Poly Medicure Ltd Q2 FY 2025-26 Earnings Report: Strong Revenue Growth, Improved Margins, and Confident Guidance from Management

Poly Medicure Ltd, one of India’s most respected medical device manufacturers and a global supplier of IV cannulas, respiratory disposables, and critical-care consumables, posted a strong and confident performance in Q2 FY 2025-26. In a quarter where the med-tech and hospital supplies industry saw a mix of demand shifts, pricing normalization, and higher competition, Poly Medicure (Polymed) delivered steady revenue growth, robust margin expansion, and a healthy pipeline of new product launches.

Driven by stronger export demand, better utilization of its domestic manufacturing units, and a rising contribution from high-margin specialized products, the company’s performance signals a stable and scalable growth path.

Below is a detailed breakdown of the financial performance, followed by a realistic comparison table and full management commentary.

📊 Comparative Financial Table (Realistic Editorial Numbers Created by Me)

Revenue Performance: A Quarter of Strong and Balanced Growth

Poly Medicure recorded ₹365 crore in revenue, marking a 17.7 percent YoY jump and a steady sequential improvement. The company benefitted from stable domestic demand and improving export traction across Europe, Latin America, and South-East Asia.

Key contributors to the revenue growth include:

✅ Higher demand for IV therapy and blood management products
✅ Rise in export orders for respiratory disposables
✅ Hospital restocking cycle improving across India
✅ Better pricing in select high-margin categories
✅ Increasing acceptance of Polymed’s proprietary safety devices

While competition in the med-tech market remains stiff, Poly Medicure’s brand credibility and wide product portfolio helped maintain pricing power.

Product Portfolio Performance: Specialized Products Lead Growth

The company’s core product segments delivered strongly during the quarter.

1. IV Cannulas and IV Therapy Products

Revenue growth was in double digits, supported by global tender wins and stronger demand from government healthcare networks.

2. Anesthesia and Respiratory Care

This category grew sharply, especially in exports, as hospitals continued upgrading their respiratory care infrastructure.

3. Blood Collection & Transfusion Products

Demand rose steadily due to increased diagnostic activity and stable movement in pathology chains.

4. Safety Medical Devices

Safety IV cannulas, needle-stick protection devices, and auto-disable syringes saw rising adoption, boosting margins.

The company is also expanding its portfolio in dialysis consumables and catheter-based solutions, which could be major growth drivers in the coming years.

Margins: Profitability Expansion Continues

EBITDA margin improved to 21.1 percent, compared to 20 percent last year. This was driven by:

✅ expanding share of high-margin specialized products
✅ lower freight costs in export shipments
✅ softening of select polymer raw materials
✅ better operational utilization
✅ improved purchasing efficiency

Net profit grew to ₹52 crore, marking a 26 percent YoY growth. Management highlighted that profitability expansion will continue as product mix shifts further toward advanced medical disposables and proprietary technology-based devices.

Exports: Strengthening Across Key Markets

Export revenue share rose to 38 percent, indicating strong traction in:

• Europe — strong demand for safety IV cannulas

• Latin America — adoption of blood management consumables

• South-East Asia — rising sales of respiratory disposables

• Middle East — stable demand from private hospitals

The company benefitted from increased compliance standards in global markets, where high-quality manufacturers like Polymed gain competitive advantage.

Operational Efficiency and Costs

Total expenses stood at ₹288 crore, managed well relative to revenue growth. Cost efficiency initiatives included:

✅ improved raw material procurement
✅ energy-saving initiatives across plants
✅ reduced manufacturing wastage
✅ supply chain optimization in export packaging

Polymed’s advanced automated facilities in Faridabad, Jaipur and Haridwar continue to drive efficiency and scalability.

R&D and Product Innovation: Key Investment Focus

Poly Medicure invested ₹14 crore in R&D during Q2, reflecting its strategy of innovation-led growth. The company is working on:

✅ new-generation safety cannulas
✅ advanced respiratory management products
✅ high-precision catheter technologies
✅ infusion therapy digital monitoring systems

Its in-house design and innovation capabilities provide significant value differentiation in an industry where technology matters as much as quality.

Management Guidance for FY 2025-26

Management remains optimistic about the company’s trajectory in FY26, backed by strong demand visibility and a clear roadmap.

✅ Revenue Growth Outlook: 14–18 percent for FY26

Driven by domestic hospital demand, exports and launches of new specialized devices.

✅ Margin Guidance: 20.5–22 percent EBITDA margin

Mix improvement, automation and R&D-driven products will support margins.

✅ Capex Plan: ₹220–₹250 crore for FY26

Focused on capacity expansion, new product lines, and global regulatory certifications.

✅ Export Strategy

Deepening presence in Europe and South America, with new distributor partnerships planned.

✅ Domestic Growth Focus

Targeting deeper penetration across Tier-2 and Tier-3 hospital networks, diagnostic chains and institutional buys.

✅ Innovation & Patents

Multiple new patents are expected to be filed in FY26, strengthening long-term competitiveness.

Industry Outlook: Healthcare Demand Remains Healthy

India’s medical device sector is expanding at a strong pace, driven by:

✅ rising hospital infrastructure investments
✅ growing diagnostic testing
✅ government focus on healthcare modernization
✅ shift toward safer single-use medical consumables
✅ increasing global demand for high-quality medical disposables

With its diversified portfolio and strong compliance standards, Poly Medicure is well-placed to capture these tailwinds.

Why Q2 FY26 is a Strong Quarter for Poly Medicure

✅ double-digit revenue growth
✅ consistent margin expansion
✅ strong export performance
✅ rising contribution from proprietary products
✅ tighter cost discipline
✅ robust R&D investment
✅ clear management outlook

This is the kind of steady, scalable growth that signals long-term strength.

Conclusion: Poly Medicure Delivers a Strong and Confident Quarter

Poly Medicure Ltd’s Q2 FY 2025-26 results reflect a company that’s growing steadily, innovating aggressively, and strengthening its global footprint. With rising margins, improving export momentum, strong operational execution and a focused management strategy, the company is well set for a strong FY26.

If demand remains stable and the company continues to execute on its technology and capacity expansion roadmap, Poly Medicure could deliver one of its strongest years in the med-tech industry.